NCT00370851 is a Phase 3 clinical trial of Avastin (Bevacizumab) in Retinal Disease, sponsored by Shahid Beheshti University of Medical Sciences.

Who is sponsoring NCT00370851?

NCT00370851 is sponsored by Shahid Beheshti University of Medical Sciences.

What drugs are being tested in NCT00370851?

Interventions in NCT00370851: Avastin (Bevacizumab).

What condition does NCT00370851 study?

NCT00370851 studies Retinal Disease.

Is NCT00370851 still recruiting?

NCT00370851 is currently completed. Last updated 23 November 2009.

Last reviewed 2009-11-23 · How we verify

NCT00370851

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial

Completed Phase 3 Last updated 23 November 2009

What this trial tests

Phase 3 trial testing Avastin (Bevacizumab) in Retinal Disease in 82 participants. Completed in 1 June 2008.

Timeline

1 August 2006

Primary endpoint
1 February 2008

1 June 2008

Quick facts

Lead sponsor	Shahid Beheshti University of Medical Sciences
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	82
Start date	1 August 2006
Primary completion	1 February 2008
Estimated completion	1 June 2008
Sites	1 location across Iran

Drugs / interventions tested

Avastin (Bevacizumab)

Conditions studied

Retinal Disease — all drugs for Retinal Disease →

Sponsor

Shahid Beheshti University of Medical Sciences

Who can join

40 and older, any sex, with Retinal Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Best corrected visual acuity
Time frame: At 12 week
Macular thickness by OCT
Time frame: At 12 week

Sponsor's own description

In this study we intend to evaluate the outcome of intravitreal avastin on improving the visual acuity and macular edema and late complications of BRVO like NVD and NVE

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.
Lees JS, Dobbin SJH, Elyan BMP, Gilmour DF, et al · · 2023 · cited 12× · PMID 36318455 · DOI 10.1093/ndt/gfac305

Verify or expand the search:

Other recruiting trials for Retinal Disease

Currently open trials in the same condition.

NCT07149740 — Data Gathering for A10900 · recruiting
NCT06852963 — A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Parti · Phase 1, PHASE2 · recruiting
NCT05699096 — Perfluorooctyl Bromide Which Empowers the Liquid to Flat the Detached Retina and Displace the Underneath Fluids Anterior · recruiting
NCT06289452 — Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis · EARLY_PHASE1 · active not recruiting
NCT06520410 — Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries · Phase 4 · recruiting

Other Shahid Beheshti University of Medical Sciences trials

Trials by the same sponsor.

NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00370851 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
Last refreshed: 23 November 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00370851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing